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INTRODUCTION
West Nile Fever (WNF) is a natural focal zoonotic arbovi-
rus infection caused by West Nile Virus (WNV), which in 
severe cases is characterized by fever, inflammation of the 
meninges and the brain matter, lymphadenopathy, mucosal 
lesions and exanthema [1].
Over the last two decades, the virus has acquired an epi-
demic potential, due to rapid global spread, the formation 
of new natural foci and the ability to cause epidemics in 
endemic regions among humans, birds and horses in many 
parts of the world. [2,3]. At present WNV circulation has 
been confirmed in 20 European countries, including close 
to Ukraine – Romania, Russia, Poland, Hungary and Slo-
vakia [4,5]. On the territory of Ukraine, the earliest reports 
of cases of WNV circulation in humans and birds relate 
to the 70s of the XX century [6,7,8]. According to experts 
from the European Center for Disease Control, during 
the last decade the proportion of seropositive individuals 
to WNV among the population of the European Union 
varies from 2.1% to 10.6% [9]. In Poltava region the first 
time laboratory confirmed WNF cases were registered in 
2011, and in general from 2011 to 2017 acute infection was 
diagnosed in 25 patients [10].
The virus is maintained in the enzootic environment 
between ornithophilic mosquitoes and certain species of 
birds with epizootic spread among animals, reptiles and 
humans [11]. Although the vast majority of patients are in-
fected with WNV in a transmission way, through mosquito 
and tick bites, other mechanisms have been described, 
including blood transfusion [12], organ transplantation 
[13], the transplacental one, breastfeeding [14], as well as 
laboratory infection cases [15].
The study of the clinical course and epidemiological 
patterns of WNF is complicated by a large number of as-
ymptomatic and subclinical forms, which generally make 
up 80-90% [11]. Conducted serological studies of WNF 
epidemics in North America and Europe have shown that 
approximately 20% of infected patients develop fever, and 
less than 1% have neuroinvasive diseases [16,17,18]. 
In recent years, in response to the introduction of manda-
tory testing of donor blood on WNV in the USA, they have 
succeeded in studying the WNF symptom complex in more 
detail [19]. Thus, during 2003-2008, a parallel survey and 
laboratory examination of blood serum samples on RNA 
was performed in WNV 1436 donors, who had seropositive 
markers of the virus during the initial screening [20]. It’s 
been found out that acute WNF occurred in 576 subjects, 
150 of them (26%) revealed clinical manifestations of the 
disease. The study revealed 8 symptoms – indicators of the 
disease, namely: headache, general weakness, fever, chills, 
severe muscle pain, joint pain, eye pain and rash [19]. An in-
teresting fact was that almost half (44%) of people diagnosed 
with acute infection had applied for medical aid on the eve 
of the day, but only 29 (5%) were diagnosed with WNF [19].
In addition to the mentioned flu-like form, 1% of people 
may develop neuroinvasive disease associated with WNV 
in the form of meningitis, encephalitis, or acute flaccid 
paralysis [21,22]. WNV meningitis is characterized by 
fever, signs of irritation of the meninges, most often – 
by rigidity of the occipital muscles, cerebral symptoms: 
severe headache, photophobia, nausea and vomiting; it 
is laboratory confirmed by changes in liquor, typical for 
aseptic serous meningitis [22]. WNV encephalitis man-
ifests itself in a wide clinical range: from disturbances of 
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consciousness to severe focal neurological injuries. As a 
rule, during the first days of the illness patients develop a 
high hyperthermia and severe intoxication syndrome, and 
from the 4th day signs of brain damage – anxiety, delirium, 
ataxia, tremor, sometimes seizures and coma are joined 
[1,16,22,23]. WNV encephalitis mortality is approximately 
20% [24,25]. According to statistics, acute flaccid paralysis 
occurs in 17.5% of patients with neuroinvasive manifes-
tations of WNF and is characterized by a predominant 
lesion of the anterior horns of the spinal cord – paresis of 
the extremities, bladder dysfunction, respiratory failure 
[26,27]. Predictors of the development of neuroinvasive 
forms of WNF are a set of factors of the pathogen (the type 
of the involved WNV strain) and the patient (age over 60, 
alcohol abuse, the presence of concomitant diseases – dia-
betes mellitus, hypertension, chronic renal failure, cancer, 
HIV infection, etc.) [25,28,29]. In addition to febrile and 
neurological symptoms in WNF, other manifestations of 
the disease have been described – chorioretinitis [30], 
hepatitis [31], pancreatitis [32], myocarditis [33], myositis 
and orchitis [34].
The main criterion for the specific diagnosis of WNV 
is the determination of immunoglobulins of the M class 
(IgM) in blood serum or spinal fluid in the dynamics (ELI-
SA), which have become positive since the 5th day of the 
illness in 98% of patients [35]. Subsequently, seroconver-
sion is observed, and immunoglobulins of the G class (IgG) 
in paired sera with an interval of 7-10 days are detected, 
the increase in their titre 4 times or more is considered 
to be the diagnostic one. In some patients specific WNV 
antibodies may be stored in serum for many years, which 
interferes the diagnosis and monitoring acute infection, 
especially in annual seasonal outbreaks [36, 37]. The false 
results of studying antibodies to WNV when infected with 
other arboviruses are also possible. Therefore, crucial in the 
diagnosis of WNF is determining the serological markers 
in paired sera. The PCR diagnosis with the determination 
of the WNV RNA is less practical, since WNF has a low 
viraemia of short duration [1,11]. 
The epidemiological and clinical patterns of WNF in 
Ukraine and Poltava region remain understudied, primarily 
due to the lack of alertness of practitioners to the problem 
of WNF and to broader access to laboratory diagnosis of 
the disease. In connection with the above matter, particular 
attention is given to examples of first clinical case of West 
Nile Viral encephalitis among the residents of Poltava region.
CLINICAL CASE
The female patient, 57 years old, was hospitalized on the 
8th day of illness into the diagnostic department of the 
Poltava Regional Clinical Infectious Disease Hospital with 
the diagnosis “Acute Respiratory Viral Infection? Entero-
virus Infection?” At hospitalization there were complaints 
about an increase in body temperature up to 39.0° C, chills, 
body pain, headache, dizziness, nausea, blurred and double 
vision, photophobia, chronic general weakness, rash. The 
patient became ill in early September, when there were 
weakness and muscle aches, since next day she had an in-
crease in body temperature to subfebrile figures (37.4° C). 
She was not under treatment and did not seek any medical 
help. During the following days there were any changes. 
The condition worsened on the 6th day of the illness, when 
the body temperature increased to 39° C, there were diz-
ziness, photophobia, blurred and double vision, headache 
and weakness, nausea and recurrent diarrhea joined, pale 
pink skin trunk rash of erythematous and papular nature 
was noticed. She applied to Poltava Regional Clinical In-
fectious Disease Hospital and was hospitalized.
From the epidemiological history: the patient lives in 
the urban-type locality of Reshetylivka in Poltava region, 
in a private house on the river bank; she has noticed mos-
quito bites; for the last 2 weeks she has not left the place 
of residence; she denies contacts with infectious patients; 
the patient eats only at home; water supply is centralized.
Objective status during hospitalization: body tempera-
ture 38.0° C, pulse of 83 beats per minute, blood pressure 
– 120/80 mmHg. General condition of moderate severity. 
AAO. The skin is of normal color, there is a diffuse pale pink 
spotted papule rash without a tendency to fuse on the skin 
of the trunk and upper extremities. The mucous membrane 
of the oropharynx is hyperemic, swollen with an enlarged 
vascular pattern, no plaque. Cervical and submandibular 
lymph nodes up to 1.0 cm in diameter can be palpated, 
they are elastic and painless. No edema. Auscultation in 
the lungs indicates vesicular breathing with no wheezing. 
Heart tons are rhythmic, moderately weakened. The tongue 
is wet and coated. Abdomen is involved into the act of 
breathing, with palpation it’s soft and painless. The liver 
and spleen are not palpable. Intestinal loops are sensitive 
when palpated and grumbling. Diuresis is adequate.
Neurological status: Awake. Eye gaps, pupils D=S, 
weakness of VI pair on both sides, diplopia when looking 
sidewards; the weakness of convergence on both sides. The 
nasolabial fold is smoothed to the right. Middle tongue. 
Arm reflexes (from the biceps, the triceps, carporadial) and 
the leg ones (knee and achilles) are high, abdominal ones 
are absent. Positive Babinski sign. Extremity strength – 5/5, 
muscle tone is normal. Surface and deep sensitivity is not 
compromised. Coordinate tests are performed satisfacto-
rily. Romberg’s test – the patient is imbalanced. Meningeal 
signs are absent.
When examining the eyeground: OD=OS, the eyes are 
open, clear, the optical medium is transparent, the disk of 
the optic nerve − the borders are not clear due to edema 
of the retina, vessels are narrowed, convoluted, macular 
reflex is enlarged, at the time of examination hemorrhage 
was not detected.
At additional examination the following changes in the 
general analysis of blood were detected − neutrophilosis 
(10%), elevated ESR (17 mm/h); in the urogram there were 
traces of protein; in the biochemical blood test elevations 
in ALT (66.3 IU/L), AST (43.1 IU/L) and LDH (483.3 
IU/L) were marked. Head MRI showed any pathological 
changes. The patient categorically refused to have a spinal 
puncture made.
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The previous diagnosis was established: “Fever of un-
known origin. Viral encephalitis?” Observation in dynamics, 
examination in accordance with the protocol for the man-
agement of patients with fever, and treatment (antibiotics, 
immunoglobulin, detoxification, anti-edema and anti-in-
flammatory drugs, hepatoprotectors) were prescribed.
On the background of ongoing therapy in the dynamics 
the patient’s condition improved: on the 3rd day body 
temperature became normal, manifestations of intoxica-
tion and cerebral syndromes (headache, dizziness, nausea) 
reduced, as well as neurological symptoms regressed, com-
pletely disappeared on the 4th-5th days. However, on the 
5th day of staying at hospital the patient noted a sudden 
deterioration of the condition − the body temperature 
increased to 39°C again, with a fever,  general weakness, 
recurrent pronounced muscle pain and headache. The 
general blood analysis showed elevated ESR up to 20 mm/h 
with the normal hemogram and biochemical blood test. 
Antipyretics were prescribed, and detoxification therapy 
was continued. Subsequently, the manifestation of the in-
toxication syndrome was regressed in 6 days, febrile fever 
lasted for 1 day and decreased litically in next 3 days. The 
rash completely regressed in 7 days, it disappeared without 
pigmentation and peeling. Manifestations of asthenic syn-
drome (weakness, fatigue) lasted for a month. The patient 
was discharged from hospital in a satisfactory condition 
on the 21st day of the illness.
According to the results of the research conducted, in 
the dynamics using ELISA IgM and IgG to WNV with 
an increase by 5 times in the titre of antibodies in paired 
sera were detected. Any other etiological factors of fever 
weren’t found out. The final diagnosis was established: 
“West Nile Fever, neuroinvasive form (encephalitis with 
predominantly sternal localization, with bilateral reflex-py-
ramidal insufficiency, and liquor-hypertensive syndrome), 
of moderate severity”.
CONCLUSIONS
The clinical case given demonstrates the typical course of 
neuroinvasive form of West Nile Fever in the type of en-
cephalitis. The beginning of the registration of West Nile 
Fever cases in Poltava region should contribute to more 
active clinical and laboratory diagnosis of this disease in 
the summer-autumn period among patients with febrile 
conditions and central nervous system injuries, who noted 
mosquito or tick bites in the case history.
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